2. Cytoskeleton Apoptosis
  3. Lysyl Oxidase Apoptosis
  4. Levoleucovorin

Levoleucovorin  (Synonyms: Levofolinic acid; Levofolene)

Cat. No.: HY-127009 Pureza: 98.53%
COA
SDS
Instrucciones de manejo Technical Support

Levoleucovorin (Levofolinic acid; Levofolene) is the pharmacologically and orally active levoisomer of Folinic acid (HY-17556), a synthetic folate analogue. Levoleucovorin can inhibit LOXL2 with an IC50 of 68.81 μM. Levoleucovorin can inhibit cancer cells proliferation, migration and induce apoptosis. Levoleucovorin can be used as a rescue agent for high-dose Methotrexate (HY-14519). Levoleucovorin can reduce the frequency of embryonic malformations. Levoleucovorin can be used for the research of can and endocrinology, such as breast cancer and osteosarcoma.

Para uso exclusivo en investigación. No vendemos a pacientes.

Levoleucovorin

Levoleucovorin Estructura química

No. CAS : 68538-85-2

Tamaño Precio Stock Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 En stock
Solution
10 mM * 1 mL in DMSO En stock
Solid
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Levoleucovorin Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Levoleucovorin (Levofolinic acid; Levofolene) is the pharmacologically and orally active levoisomer of Folinic acid (HY-17556), a synthetic folate analogue. Levoleucovorin can inhibit LOXL2 with an IC50 of 68.81 μM. Levoleucovorin can inhibit cancer cells proliferation, migration and induce apoptosis. Levoleucovorin can be used as a rescue agent for high-dose Methotrexate (HY-14519). Levoleucovorin can reduce the frequency of embryonic malformations. Levoleucovorin can be used for the research of can and endocrinology, such as breast cancer and osteosarcoma[1][2][3].

IC50 & Target[1]

LOXL2

68.81 nM (IC50)

In Vitro

Levoleucovorin inhibits recombinant human LOXL2 protein with an IC50 of 68.81 μM[1].
Levoleucovorin (72 h) inhibits proliferation of MDA-MB 231 breast cancer cells with a GI50 of 55.91 μM and MCF-7 breast cancer cells with a GI50 of 79.20 μM[1].
Levoleucovorin (15-60 μM; 12 h) dose-dependently inhibits HGF-induced trans-endothelial migration of MDA-MB 231 and MCF-7 breast cancer cells across HUVEC cell layers[1].
Levoleucovorin (30-80 μM；72 h) induces dose-dependent apoptosis in MDA-MB 231 and MCF-7 breast cancer cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Levoleucovorin Related Antibodies

Apoptosis Analysis[1]

Cell Line: MDA-MB 231 breast cancer cell line, MCF-7 breast cancer cell line
Concentration: 30 μM, 60 μM (MDA-MB 231); 40 μM, 80 μM (MCF-7)
Incubation Time: 72 h
Result: Significantly increased Annexin V-positive early and late apoptotic populations in MDA-MB 231 cells in a dose-dependent manner, with total apoptosis increasing 17.93% at 30 μM and 33.11% at 60 μM.
Significantly increased Annexin V-positive early and late apoptotic populations in MCF-7 cells in a dose-dependent manner, with total apoptosis increasing 15.36% at 40 μM and 30.38% at 80 μM.
In Vivo

Levoleucovorin (10.75-43 μmol/kg per day; i.g.,; daily; initiated 2 weeks pre-mating through gestation) reduces the frequency of embryonic malformations in a dose-dependent manner, with the 43 μmol/kg per day dose lowering overall malformation frequency to 33.3%[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Folbp1 knockout (female; mated to Folbp1-/- males; prenatal developmental model)[3]
Dosage: 10.75 μmol/kg per day; 21.5 μmol/kg per day; 43 μmol/kg per day
Administration: I.g.; daily; initiated 2 weeks pre-mating through gestation
Result: Reduced malformation frequency to 66.7% at 10.75 μmol/kg per day, 65.8% at 21.5 μmol/kg per day, and 33.3% at 43 μmol/kg per day.
Decreased neural tube defects to 35.2% (10.75 and 21.5 μmol/kg), 16.7% (43 μmol/kg).
Decreased craniofacial defects to 46.2% (10.75 and 21.5 μmol/kg), 19.4% (43 μmol/kg).
Demonstrated significant inverse dose-dependent relationship with all malformation categories.
Resulted in a mean litter size of 3.70 ± 2.63 at 43 μmol/kg per day, significantly lower than wild-type controls.
Peso molecular

473.44

Fòrmula

C20H23N7O7
No. CAS
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=CN1C2=C(NC(N)=NC2=O)NC[C@@H]1CNC3=CC=C(C=C3)C(N[C@H](C(O)=O)CCC(O)=O)=O
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvente y solubilidad
In Vitro: 

DMSO : 35 mg/mL (73.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 33.33 mg/mL (70.40 mM; ultrasonic and adjust pH to 11 with 1 M NaOH)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1122 mL 10.5610 mL 21.1220 mL
5 mM 0.4224 mL 2.1122 mL 4.2244 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureza y Documentación
Referencias

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 2.1122 mL 10.5610 mL 21.1220 mL 52.8050 mL
5 mM 0.4224 mL 2.1122 mL 4.2244 mL 10.5610 mL
10 mM 0.2112 mL 1.0561 mL 2.1122 mL 5.2805 mL
15 mM 0.1408 mL 0.7041 mL 1.4081 mL 3.5203 mL
20 mM 0.1056 mL 0.5281 mL 1.0561 mL 2.6403 mL
25 mM 0.0845 mL 0.4224 mL 0.8449 mL 2.1122 mL
30 mM 0.0704 mL 0.3520 mL 0.7041 mL 1.7602 mL
40 mM 0.0528 mL 0.2640 mL 0.5281 mL 1.3201 mL
50 mM 0.0422 mL 0.2112 mL 0.4224 mL 1.0561 mL
60 mM 0.0352 mL 0.1760 mL 0.3520 mL 0.8801 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Levoleucovorin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Levoleucovorin68538-85-2Levofolinic acid LevofoleneLysyl OxidaseApoptosisHUVECbreast cancerFolbp1-/- mouse embryosMCF-7LOXL2Folbp1-/- damsMDA-MB 231Inhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Levoleucovorin
Cat. No.:
HY-127009
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.